The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index; none of the 27 sources its claims cite is checked for support yet.
Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone
Open accessAbstract
Insulin resistance is associated with a decreased vasodilator response to insulin. Because insulin's vasodilator effect is nitric oxide dependent, this impairment may reflect endothelial dysfunction. Troglitazone, an insulin-sensitiser, might thus improve insulin-dependent and/or endothelium-dependent vascular function in insulin resistant obese subjects. For 8 weeks, fifteen obese subjects were treated with either 400 mg troglitazone once daily or placebo, in a randomised, double-blind, cross-over design. At the end of each treatment period, we measured forearm vasodilator responses (plethysmography) to intra-arterial administered acetylcholine and sodium nitroprusside; insulin sensitivity and insulin-induced vascular and neurohumoral responses (clamp); vasoconstrictor responses to NC-monomethyl-L-arginine (L-NMMA) during hyperinsulinaemia; and ambulatory 24-h blood pressure (ABPM). Baseline data (placebo) of obese subjects were compared with those obtained in lean control subjects. Obese subjects were insulin resistant compared with leans (whole-body glucose uptake: 26.8+/-3.0 vs. 53.9+/-4.3 [tmol kgl min-, p < 0.001). Troglitazone improved whole-body glucose uptake (to 31.9+/-3.3 micromol x kg(-1) x min(-1) , p=0.028), and forearm glucose uptake (from 1.09+/-0.54 to 2.31+/-0.69 micromol dL(-1) x min(-1), p=0.006). Insulin-induced vasodilatation was blunted in obese subjects (percent increase in forearm blood flow (FBF) in lean 66.5+/-23.0%, vs. 10.1+/-11.3% in obese, p=0.04), but did not improve during troglitazone. Vascular responses to acetylcholine, sodium nitroprusside and L-NMMA did not differ between the obese and lean group, nor between both treatment periods in the obese individuals. In conclusion, in insulin resistant obese subjects, endothelial vascular function is normal despite impaired vasodilator responses to insulin. Troglitazone improved insulin sensitivity but it had no effects on endothelium-dependent and -independent vascular responses. These data do not support an association between insulin resistance and endothelial function.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In obese, insulin-resistant, normotensive adults, insulin-induced forearm vasodilatation was blunted compared with lean controls, but endothelium-dependent and endothelium-independent vascular responses were preserved. Troglitazone modestly improved insulin sensitivity without restoring insulin-mediated vasodilatation or altering endothelial function.
Key findings
- Obese subjects were insulin resistant: whole-body glucose uptake was 26.8 ± 3.0 vs 53.9 ± 4.3 mmol × kg⁻¹ × min⁻¹ in lean subjects (p < 0.001). Insulin-induced forearm blood flow increased 10.1 ± 11.3% in obese vs 66.5 ± 23.0% in lean subjects (p = 0.04).
- Vascular responses to acetylcholine, sodium nitroprusside, and L-NMMA were not different between lean and obese subjects and were not affected by troglitazone.
- Troglitazone improved whole-body glucose uptake to 31.9 ± 3.3 mmol × kg⁻¹ × min⁻¹ (p = 0.028) and insulin-induced forearm glucose uptake to 2.31 ± 0.69 mmol × dl⁻¹ × min⁻¹ (p = 0.006 vs placebo), but did not change insulin-induced vasodilatation (2.2 ± 4.9%, p = NS vs placebo).
- No significant correlation was observed between vascular responses to acetylcholine and insulin sensitivity (r = 0.20, p = NS); the correlation between insulin-induced change in blood flow and whole-body glucose uptake was r = 0.39 (p = 0.056).
Methods
- Randomized, placebo-controlled, double-blind crossover trial in 15 obese healthy volunteers (BMI 27–36 kg/m², age 25–50 years, normotensive) and 13 age- and sex-matched lean controls; treatment was troglitazone 400 mg/day or placebo for 8 weeks with a 2-week washout. Vascular responses were assessed in 13 obese subjects.
- Forearm blood flow was measured by venous occlusion plethysmography during intra-arterial acetylcholine, sodium nitroprusside, and L-NMMA, plus a euglycaemic hyperinsulinaemic clamp (insulin 430 pmol × m⁻² × min⁻¹ for 120 min); 24-h ambulatory blood pressure was also monitored.
- Analyses used paired and unpaired t tests, repeated measures ANOVA, and Spearman correlations; significance was set at p < 0.05.
Limitations
- The paper states that it cannot exclude that a more pronounced increase in insulin sensitivity might result in greater insulin-mediated vasodilatation, and that no pharmacological therapy currently achieves this target.
- The paper notes the study duration may have been relatively short, troglitazone effects were modest and variable between individuals, and a full dose-response curve of insulin on blood flow could not be constructed.
- Evident from the text: the sample was small (15 obese, 13 lean; vascular responses in 13 obese), one obese subject was excluded from the troglitazone portion after surgery/complications and 6.4 kg weight loss, and one subject had near syncope during a clamp but her data were included.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
37 Own result · 21 Not checked yet · 10 Own method · 7 Own interpretation · 4 No basis given
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“responses to endothelium-dependent as well as independent vasodilators were absolutely similar with those in the lean group.”
§ Insulin > Discussion
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Troglitazone did not affect the absolute or relative vascular responses to nitroprusside (Fig. 2, lower panel).”
§ Insulin > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Acetylcholine induced a dose-dependent increase in FBF in the experimental arm.”
§ Insulin > Results
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Infusion of sodium nitroprusside induced a dosedependent increase in FBF in the experimental arm.”
§ Insulin > Results
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Responses in the obese group were not different from those in lean subjects and were not affected by troglitazone.”
§ Insulin > Haemodynamic parameters.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“mean whole-body glucose uptake was 26.8 ± 3.0 (range 11.9±46.1),compared to 53.9 ± 4.3 (range 32.7±92.2) mmol × kg ±1 × min ±1 in lean subjects (p < 0.001).”
§ Insulin > Metabolic response to euglycaemic hyperinsulinaemic clamping.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“L-NMMA infusion during systemic hyperinsulinaemia induced a dose-dependent vasoconstrictor response in the experimental arm in both groups.”
§ Insulin > Haemodynamic parameters.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Insulin-induced vasodilatation was blunted in the obese group; FBF in the control arm from 1.87 ± 0.22 to 1.95 ± 0.19 ml × dl ±1 × min ±1 (p = NS vs. baseline), percentage increase in FBF 10.1 ± 11.3 % (p = 0.04 vs. lean group).”
§ Insulin > Haemodynamic parameters.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The absolute or relative vascular responses were not different between lean and obese, nor were they affected by troglitazone (Fig. 2, upper panel).”
§ Insulin > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Body weight did not significantly change during both treatment periods (placebo: + 0.75 ± 0.46 kg, troglitazone: + 0.41 ± 0.48 kg, p = NS).”
§ Insulin > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 22
- The quote only partly states this claim. 2
- Probably not a substantial claim. 20
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The absolute or relative vascular responses were not different between lean and obese, nor were they affected by troglitazone (Fig. 2, upper panel).”
§ Insulin > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“However the changes under these strictly double-blind placebo-controlled conditions were modest and largely variable between individuals.”
§ Insulin > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Mean ambulatory 24-h diastolic blood pressure decreased during treatment with troglitazone, mean ambulatory 24-h systolic blood pressure did not change (Table 2).”
§ Insulin > Haemodynamic parameters.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The number of subjects in our study was larger than in Steinberg's study.”
§ Insulin > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Mean plasma triglycerides (TG) and NEFA levels were higher, and HDL-cholesterol levels lower in the obese group.”
§ Insulin > Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Treatment with troglitazone did not change baseline arterial NE concentration nor the insulin-induced absolute or percentual increase in NE (all p = NS vs. placebo) (Table 3).”
§ Insulin > Haemodynamic parameters.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Troglitazone treatment was associated with slight decrements in NEFA (from 0.61 ± 0.07 to 0.47 ± 0.05 mmol × l ±1 , p = 0.06)”
§ Insulin > Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“total cholesterol, HDL-cholesterol and TG concentrations did not significantly change.”
§ Insulin > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Eight weeks of treatment with Troglitazone improved total-body as well as forearm insulin-mediated glucose uptake and tended to lower fasting insulin concentration.”
§ Insulin > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Responses in blood pressure and heart rate to insulin were not different between the two groups and were not influenced by troglitazone.”
§ Insulin > Haemodynamic parameters.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was a clear difference with respect to weight, fat percentage and waist/hip ratio.”
§ Insulin > Results
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one. The quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, ambulatory diastolic blood pressure decreased slightly, and elevated NEFA lev-els showed a tendency to improve.”
§ Insulin > Discussion
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Insulin infusion increased systolic but not diastolic blood pressure in both groups.As a result, pulse pressure increased significantly (Table 3).”
§ Insulin > Haemodynamic parameters.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Obese subjects in our group exhibited well known features of the insulin resistance syndrome [38], with insulin sensitivity clearly different from lean subjects.”
§ Insulin > Discussion
What the sources say
- Not checked yetcites [38]
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although all individuals were normotensive, mean office diastolic blood pressure was higher in the obese group.”
§ Insulin > Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“in NIDDM [10,11] and hypertension [12], an impaired endothelial function has been reported.”
§ Insulin > Abstract
What the sources say
- Not checked yetcites [10]
- Not checked yetcites [11]
- Not checked yetcites [12]
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Recent reports indeed claim a reduced vasodilator response to metacholine and not to sodium nitroprusside in insulin resistant obese individuals indicating a specific defect in endothelial-dependent vasodilatation [13].”
§ Insulin > Abstract
What the sources say
- Not checked yetcites [13]
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Between both treatment periods there was a two week wash-out period.”
§ Insulin > Subjects.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Statistical analyses were only performed after prior verification of appropriateness by exclusion of period or sequence effects [22].”
§ Insulin > Measurements.
What the sources say
- Not checked yetcites [22]
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“In this study, obesity represents a situation of ªpureº insulin resistance, with the advantage that changes in insulin sensitivity are not confounded by changes in blood glucose concentrations (ªglucose toxicityº) [37].”
§ Insulin > Discussion
What the sources say
- Not checked yetcites [37]
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Recently, in uncomplicated NIDDM, no correlation was observed between an index of in vivo NO generation and insulin sensitivity [32].”
§ Insulin > Discussion
What the sources say
- Not checked yetcites [32]
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Identical changes occurred when FVR instead of FBF was used for analyses.”
§ Insulin > Haemodynamic parameters.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Troglitazone improves metabolic parameters related to insulin sensitivity, but it does not change the effect of insulin on vascular tone nor on endothelial function.”
§ Insulin > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Their study population (although strictly speaking normotensive), had higher blood pressure values (mean arterial pressure (MAP) » 100 mmHg) than ours (MAP » 92.5 mmHg), possibly explaining part of the observed differences [12].”
§ Insulin > Discussion
What the sources say
- Not checked yetcites [12]
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The absence of a specific defect in vascular endothelial function in obese, insulin-resistant subjects, despite a diminished insulin-induced vasodilatation, suggests that alternative mechanisms may be responsible for insulin-mediated vasodilatation.”
§ Insulin > Discussion
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“hypercholesterolaemia, a disorder that is firmly associated with disturbed endothelial function [33]”
§ Insulin > Discussion
What the sources say
- Not checked yetcites [33]
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Troglitazone was well tolerated, drug compliance was more than 95 %.”
§ Insulin > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“During infusion of acetylcholine, nitroprusside and L-NMMA infusions, intra-arterial blood pressure remained stable throughout (data not shown).”
§ Insulin > Haemodynamic parameters.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The subjects, pharmacists and investigators were not aware of the treatment code which was broken only after completion of all analyses.”
§ Insulin > Subjects.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Compliance was monitored by pill counts and diary records.”
§ Insulin > Subjects.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“To avoid interference with the previously administered vasodilator drugs in the experimental arm (see Fig. 1, schedule of the protocol), changes in FBF in the control arm were used for statistical evaluation of the effect of insulin on blood flow.”
§ Insulin > Measurements.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“perhaps reflecting a specific beneficial drug effect on skeletal muscle glucose uptake.”
§ Insulin > Discussion
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“we performed a randomised, placebo-controlled, double-blind crossover trial with troglitazone in obese individuals characterised by insulin resistance.”
§ Insulin > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
In the paper
“Steinberg et al. used metacholine instead of acetylcholine as endothelial-dependent vasodilator, which may not be purely nitric oxide dependent [30].”
§ Insulin > Discussion
What the sources say
- Not checked yetcites [30]
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“These treatment results of troglitazone are consistent with earlier studies in humans [15±17].”
§ Insulin > Discussion
What the sources say
- Not checked yetcites [15±17]
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“There were no sequence or period effects during the trial; mean weight change, fasting plasma glucose/insulin, lipid levels, insulin sensitivity and blood pressure were comparable during the first and second period of the trial.”
§ Insulin > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“the role of ATP-dependent potassium channels [35] and Na + -K + -ATPase [36] has been reported as alternative mechanisms for insulin-induced vasodilatation”
§ Insulin > Discussion
What the sources say
- Not checked yetcites [35]
- Not checked yetcites [36]
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Coefficients of plasma glucose variation during the last 30 min of the clamp were 3.1 ± 04 % in obese and 4.4 ± 0.7 % in lean subjects.”
§ Insulin > Measurements.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Although baseline FBF was not significantly different between both groups, FBF tended to be higher in the obese group.To compensate for these possible differences in baseline flow, responses to drugs were also expressed as percentage increase above baseline [23].”
§ Insulin > Measurements.
What the sources say
- Not checked yetcites [23]
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The authors state this as an assumption.
Whole blood glucose equals (1 - 0.3 × haematocrit) × plasma blood glucose.
“Assuming that whole blood glucose = (1±0.3´haematocrit) ´plasma blood glucose [20]”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Despite a clear improvement in insulin sensitivity with treatment, no improvement in insulin-mediated or agonist-stimulated vasodilation was seen.”
From Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus (2001) · cites this paper as [32]
Citations
Cites
Abnormal Endothelium-Dependent Vascular Relaxation in Patients with Essential Hypertension
Panza, J. A., Quyyumi, A. A., Brush, J. E., & Epstein, S. E. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007053230105 · Cited by 2,366
Steinberg, H. O., Chaker, H., Leaming, R., Johnson, A., Brechtel, G., & Baron, A. D. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118709 · Cited by 1,687 · cited 2×
“Recent reports indeed claim a reduced vasodilator response to metacholine and not to sodium nitroprusside in insulin resistant obese individuals indicating a specific defect in endothelial-dependent vasodilatation [13].”
BackgroundThe two‐period cross‐over clinical trial.
Hills, M., & Armitage, P. (1979) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1979.tb05903.x · Cited by 1,399
Steinberg, H. O., Brechtel, G., Johnson, A., Fineberg, N. S., & Baron, A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117433 · Cited by 1,216
Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans.
Anderson, E. A., Hoffman, R. P., Balon, T. W., Sinkey, C. A., & Mark, A. L. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115260 · Cited by 1,075
Assessment of Insulin Sensitivityin Vivo*
Bergman, R. N., Finegood, D. T., & Ader, M. (1985) · Endocrine Reviews · doi:10.1210/edrv-6-1-45 · Cited by 1,072
Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes
Saltiel, A. R., & Olefsky, J. M. (1996) · Diabetes · doi:10.2337/diab.45.12.1661 · Cited by 1,050
Laakso, M., Edelman, S. V., Brechtel, G., & Baron, A. D. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114644 · Cited by 930
McVeigh, G. E., Brennan, G. M., Johnston, G. D., McDermott, B. J., McGrath, L. T., Henry, W. R., Andrews, J. W., & Hayes, J. R. (1992) · Diabetologia · doi:10.1007/bf00429099 · Cited by 916
Improvement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with Troglitazone
Nolan, J. J., Ludvik, B. H., Beerdsen, P., Joyce, M., & Olefsky, J. M. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411033311803 · Cited by 914
Cited by
Sorted by citations
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Kinaan, M., Ding, H., & Triggle, C. R. (2015) · Medical Principles and Practice · doi:10.1159/000381643 · Cited by 1,515
Cardiovascular Actions of Insulin
Muniyappa, R., Montagnani, M., Koh, K. K., & Quon, M. J. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0006 · Cited by 888
Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome.
Hadi, H. A. R., Carr, C. S., & Suwaidi, J. M. S. A. (2005) · PubMed Central · Cited by 807
Rocca, H. B., Cockcroft, J., Deanfield, J. E., Donald, A. E., Ferrannini, E., Halcox, J., Kiowski, W., ̈scher, T. F. L., Mancia, G., Natali, A., et al. (2005) · Journal of Hypertension · doi:10.1097/00004872-200502000-00001 · Cited by 763
Diabetes and Endothelial Dysfunction: A Clinical Perspective
Calles-Escandón, J., & Cipolla, M. J. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.1.0417 · Cited by 657
Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
Wang, L., Waltenberger, B., Pferschy‐Wenzig, E., Blunder, M., Liu, X., Malainer, C., Blažević, T., Schwaiger, S., Rollinger, J. M., Heiß, E. H., et al. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.018 · Cited by 617
Role of insulin resistance in endothelial dysfunction
Muniyappa, R., & Sowers, J. R. (2013) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-012-9229-1 · Cited by 539
Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus
Mather, K. J., Verma, S., & Anderson, T. J. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01129-9 · Cited by 513
Volpi, E., Mittendorfer, B., Rasmussen, B. B., & Wolfe, R. R. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.12.7021 · Cited by 464
Balletshofer, B. M., Rittig, K., Enderle, M. D., Volk, A., Maerker, E., Jacob, S., Matthaei, S., Kristian, R. E. T. T., & Häring, H. U. (2000) · Circulation · doi:10.1161/01.cir.101.15.1780 · Cited by 437
Surdacki, A., Nowicki, M. P., Sandmann, J., Tsikas, D., Boeger, R. H., Bode-Boeger, S. M., Kruszelnicka-Kwiatkowska, O., Kokot, F., Dubiel, J. S., & Froelich, J. C. (1999) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199904000-00020 · Cited by 422
Nonhypoglycemic Effects of Thiazolidinediones
Parulkar, A., Pendergrass, M., Granda-Ayala, R., Lee, T. R., & Fonseca, V. A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-1-200101020-00014 · Cited by 412
Collins, A. R., Meehan, W. P., Kintscher, U., Jackson, S. M., Wakino, S., Noh, G. J., Palinski, W., Hsueh, W. A., & Law, R. E. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.21.3.365 · Cited by 389
Barrett, E. J., Eggleston, E. M., Inyard, A. C., Wang, H., Li, G., Chai, W., & Liu, Z. (2009) · Diabetologia · doi:10.1007/s00125-009-1313-z · Cited by 323
Pathophysiological implications of insulin resistance on vascular endothelial function
Wheatcroft, S. B., Williams, I. L., Shah, A. M., & Kearney, M. T. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00869.x · Cited by 316
Prevention Conference VI: Diabetes and Cardiovascular Disease
Howard, B. V., Rodríguez, B. L., Bennett, P. H., Harris, M. I., Hamman, R. F., Kuller, L. H., Pearson, T. A., & Wylie‐Rosett, J. (2002) · Circulation · doi:10.1161/01.cir.0000013953.41667.09 · Cited by 307
Obesity Blunts Insulin-Mediated Microvascular Recruitment in Human Forearm Muscle
Clerk, L. H., Keske, M. A., Jahn, L. A., Liu, Z., Lindner, J. R., & Barrett, E. J. (2006) · Diabetes · doi:10.2337/db05-1373 · Cited by 305
Metabolic and Additional Vascular Effects of Thiazolidinediones
Martens, F. M. A. C., Visseren, F. L. J., Lemay, J., de Koning, E. J. P., & Rabelink, T. J. (2002) · Drugs · doi:10.2165/00003495-200262100-00004 · Cited by 290
Moens, A. L., Goovaerts, I., Claeys, M. J., & Vrints, C. J. (2005) · CHEST Journal · doi:10.1378/chest.127.6.2254 · Cited by 277
Regulation of obesity and insulin resistance by nitric oxide
Sansbury, B. E., & Hill, B. G. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.05.016 · Cited by 274
“The fact that obesity in humans is associated with decreased blood flow in response to methacholine [230], bradykinin [231,232], substance P and acetylcholine [232], shear stress [233], and insulin [234,235] seems to suggest that the”
BackgroundFujita, S., Rasmussen, B. B., Cadenas, J. G., Grady, J. J., & Volpi, E. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00271.2005 · Cited by 278
Antioxidants, diabetes and endothelial dysfunction
Laight, D. W. (2000) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00054-7 · Cited by 264
Williams, I. L., Wheatcroft, S. B., Shah, A. M., & Kearney, M. T. (2002) · International Journal of Obesity · doi:10.1038/sj.ijo.0801995 · Cited by 265
Physiologic Hyperinsulinemia Enhances Human Skeletal Muscle Perfusion by Capillary Recruitment
Coggins, M. P., Lindner, J. R., Rattigan, S., Jahn, L. A., Fasy, E. A., Kaul, S., & Barrett, E. J. (2001) · Diabetes · doi:10.2337/diabetes.50.12.2682 · Cited by 260
Stirban, A. O., Negrean, M., Stratmann, B., Gawlowski, T., Horstmann, T., Götting, C., Kleesiek, K., Müller-Rösel, M., Koschinsky, T., Uribarri, J., et al. (2006) · Diabetes Care · doi:10.2337/dc06-0531 · Cited by 262
The Metabolic Syndrome and Inflammation
Sutherland, J. P., McKinley, B., & Eckel, R. H. (2004) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2004.2.82 · Cited by 243
Pistrosch, F., Passauer, J., Fischer, S., Fuecker, K., Hanefeld, M., & Gross, P. A. (2004) · Diabetes Care · doi:10.2337/diacare.27.2.484 · Cited by 225
Prevention Conference VI: Diabetes and Cardiovascular Disease
Eckel, R. H., Wassef, M. K., Chait, A., Sobel, B. E., Barrett, E. J., King, G. L., Lopes-Virella, M. F., Reusch, J. E. B., Ruderman, N. B., Steiner, G. A., et al. (2002) · Circulation · doi:10.1161/01.cir.0000013954.65303.c5 · Cited by 199
Raitakari, M., Ilvonen, T., Ahotupa, M., Lehtimäki, T., Harmoinen, A., Suominen, P., Elo, J., Hartiala, J., & Raitakari, O. T. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000109749.11042.7c · Cited by 198
Natali, A., Toschi, E., Baldeweg, S. E., Ciociaro, D., Favilla, S., Saccà, L., & Ferrannini, E. (2006) · Diabetes · doi:10.2337/diabetes.55.04.06.db05-1076 · Cited by 200
van Asseldonk, E. J. P., Stienstra, R., Koenen, T. B., Joosten, L. A. B., Netea, M. G., & Tack, C. J. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2992 · Cited by 165
Self-citationCaballero, A. E., Saouaf, R., Lim, S. C., Hamdy, O., Abou-Elenin, K., O'Connor, C., LoGerfo, F. W., Horton, E. S., & Veves, A. (2003) · Metabolism · doi:10.1053/meta.2003.50023 · Cited by 154
Wang, T., Chen, W., Lin, J., Chen, M.-F., & Lee, Y. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.10.022 · Cited by 151
The link between metabolic abnormalities and endothelial dysfunction in type 2 diabetes: An update
Zhang, H., Dellsperger, K. C., & Zhang, C. (2012) · Basic Research in Cardiology · doi:10.1007/s00395-011-0237-1 · Cited by 144
Richards, O. C., Raines, S. M., & Attie, A. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0035 · Cited by 150
Eid, H. M. A., Arnesen, H., Hjerkinn, E. M., Lyberg, T., & Seljeflot, I. (2004) · Metabolism · doi:10.1016/j.metabol.2004.06.026 · Cited by 139
In Vivo Actions of Peroxisome Proliferator–Activated Receptors
Eldor, R., DeFronzo, R. A., & Abdul‐Ghani, M. A. (2013) · Diabetes Care · doi:10.2337/dcs13-2003 · Cited by 128
Obesity and Coronary Heart Disease
Alexander, J. K. (2001) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200104000-00002 · Cited by 125
Insulin Action in the Vasculature: Physiology and Pathophysiology
Mather, K. J., Anderson, T. J., & Verma, S. (2001) · Journal of Vascular Research · doi:10.1159/000051074 · Cited by 123
Microvascular Dysfunction Is Associated With a Higher Incidence of Type 2 Diabetes Mellitus
Muris, D. M. J., Houben, A. J. H. M., Schram, M. T., & Stehouwer, C. D. A. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300291 · Cited by 121
Eringa, E. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00593-x · Cited by 118
Scherrer, U., & Sartori, C. S. (2000) · European Journal of Endocrinology · doi:10.1530/eje.0.1420315 · Cited by 117
Physiological and Therapeutic Roles of Peroxisome Proliferator-Activated Receptors
Berger, J. P., & Wagner, J. A. (2002) · Diabetes Technology & Therapeutics · doi:10.1089/15209150260007381 · Cited by 107
Majithiya, J. B., PARAMAR, A., & Balaraman, R. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.12.025 · Cited by 106
Martens, F. M. A. C., Visseren, F. L. J., de Koning, E. J. P., & Rabelink, T. J. (2005) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000187176.13403.05 · Cited by 105
Munir, K. M., Chandrasekaran, S., Gao, F., & Quon, M. J. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00377.2013 · Cited by 103
Rask‐Madsen, C., Ihlemann, N., Krarup, T., Christiansen, E., Køber, L., Kistorp, C. N., & Torp-Pedersen, C. T. (2001) · Diabetes · doi:10.2337/diabetes.50.11.2611 · Cited by 106
Esteve, E., Castro, A., López‐Bermejo, A., Vendrell, J. J., Ricart, W., & Fernández‐Real, J. M. (2007) · Diabetes Care · doi:10.2337/dc06-1793 · Cited by 98
Can Metformin Exert as an Active Drug on Endothelial Dysfunction in Diabetic Subjects
Salvatore, T., Pafundi, P. C., Galiero, R., Rinaldi, L., Caturano, A., Vetrano, E., Aprea, C., Albanese, G., Di Martino, A., Ricozzi, C., et al. (2020) · Biomedicines · doi:10.3390/biomedicines9010003 · Cited by 97
Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis
Vosper, H., Khoudoli, G. A., Graham, T. L., & Palmer, C. N. A. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00232-2 · Cited by 95
Insulin resistance and endothelial cell dysfunction: studies in mammalian models
Kearney, M. T., Duncan, E. R., Kahn, M., & Wheatcroft, S. B. (2007) · Experimental Physiology · doi:10.1113/expphysiol.2007.039172 · Cited by 89
Mechanisms, Significance and Treatment of Vascular Dysfunction in Type 2 Diabetes Mellitus
Woodman, R. J., Chew, G. T., & Watts, G. F. (2005) · Drugs · doi:10.2165/00003495-200565010-00003 · Cited by 83
Improved insulin sensitivity by anti-TNFα antibody treatment in patients with rheumatic diseases
Huvers, F. C., Popa, C. D., Netea, M. G., van den Hoogen, F. H. J., & Tack, C. J. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062323 · Cited by 82
Self-citationGlucose transport in brain and retina: implications in the management and complications of diabetes
Kumagai, A. K. (1999) · Diabetes/Metabolism Research and Reviews · doi:10.1002/(sici)1520-7560(199907/08)15:4 · Cited by 159
Insulin resistance and endothelial dysfunction
Yki‐Järvinen, H. (2003) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/s1521-690x(03)00033-2 · Cited by 77
Insulin resistance, lipotoxicity and endothelial dysfunction
Imrie, H., Abbas, A., & Kearney, M. T. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.09.025 · Cited by 74
Sartoretto, J. L., de Melo, G. D. A. N., de Carvalho, M. H. C., Nigro, D., Tostes, R. C., Scavone, C., Cuman, R. K. N., & Fortes, Z. B. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.05.022 · Cited by 73
Metabolomic analyses for atherosclerosis, diabetes, and obesity
Du, F., Virtue, A. T., Wang, H., & Yang, X. (2013) · Biomarker Research · doi:10.1186/2050-7771-1-17 · Cited by 70
Tan, M., Chang, S.-Y., Chang, D., Tsai, J. C. ‐., & Lee, Y. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021453 · Cited by 70
Ginsberg, H. N., Plutzky, J., & Sobel, B. E. (1999) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/204748739900600512 · Cited by 69
Parker, J. C. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00093-5 · Cited by 69
Solomon, T. P. J., Haus, J. M., Li, Y., & Kirwan, J. P. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2069 · Cited by 68
Lipaemia, Inflammation and Atherosclerosis
van Oostrom, A. J. H. H. M., van Wijk, J. P. H., & Cabezas, M. C. (2004) · Drugs · doi:10.2165/00003495-200464002-00004 · Cited by 67
Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease
Fonseca, V. A. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00616-7 · Cited by 67
Insulin, nitric oxide and the sympathetic nervous system
Sartori, C. S., & Scherrer, U. (1999) · Journal of Hypertension · doi:10.1097/00004872-199917110-00003 · Cited by 67
The effects of thiazolidinediones on blood pressure levels – A systematic review
Sarafidis, P. A., & Nilsson, P. M. (2006) · Blood Pressure · doi:10.1080/08037050600853720 · Cited by 64
The SWELL1-LRRC8 complex regulates endothelial AKT-eNOS signaling and vascular function
Alghanem, A. F., Ta, C. M., Maurer, J. M., Gunasekar, S. K., Kumar, A., Fatima, U., Kang, C., Xie, L., Adeola, O., Abello, J., et al. (2021) · eLife · doi:10.7554/elife.61313 · Cited by 66
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance
STOLAR, M. W., & CHILTON, R. J. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80240-0 · Cited by 65
Houben, A. J. H. M., Eringa, E. C., Jonk, A. M., Serné, E. H., Smulders, Y. M., & Stehouwer, C. D. A. (2011) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-011-0214-0 · Cited by 62
Carmassi, F., Negri, F. D., Fioriti, R., Giorgi, A. D., Giannarelli, C., Fruzzetti, F., Pedrinelli, R., Dell’Omo, G., & Bersi, C. (2005) · Thrombosis Research · doi:10.1016/j.thromres.2004.11.026 · Cited by 62
Kato, T., Inoue, T., & Node, K. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-12 · Cited by 61
Troglitazone Improves Endothelial Dysfunction in Patients with Insulin Resistance
Watanabe, Y., Sunayama, S., Shimada, K., Sawano, M., Hoshi, S.-I., Iwama, Y., Mokuno, H., Daida, H., & Yamaguchi, H. (2000) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat1994.7.159 · Cited by 60
Sivitz, W. I., Wayson, S. M., Bayless, M., Sinkey, C. A., & Haynes, W. G. (2007) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2005.12.003 · Cited by 59
Tooke, J. E., & Goh, K. L. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00099.x · Cited by 59
Altered renal microvascular response in Zucker obese rats
Hayashi, K., Kanda, T., Homma, K., Tokuyama, H., Okubo, K., Takamatsu, I., Tatematsu, S., Kumagai, H., & Saruta, T. (2002) · Metabolism · doi:10.1053/meta.2002.36311 · Cited by 56
Wu, L., Wang, R., deChamplain, J., & Tw, W. (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.04.010 · Cited by 55
Role of flavonoids in controlling obesity: molecular targets and mechanisms
Mahboob, A., Samuel, S. M., Mohamed, A., Wani, M. Y., Ghorbel, S., Miled, N., Büsselberg, D., & Châari, A. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1177897 · Cited by 60
Obesity and Endothelial Dysfunction
Shankar, S. S., & Steinberg, H. O. (2005) · Seminars in Vascular Medicine · doi:10.1055/s-2005-871742 · Cited by 51
Peroxisome Proliferator-Activated Receptors and the Cardiovascular System
Chen, Y. E., Fu, M., Zhang, J., Zhu, X., Lin, Y., Akinbami, M. A., & Song, Q. (2003) · Vitamins and hormones · doi:10.1016/s0083-6729(03)01005-7 · Cited by 50
Rationale for and role of thiazolidinediones in type 2 diabetes mellitus
Lebovitz, H. E. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02557-2 · Cited by 51
Wendelhag, I., Fagerberg, B., Hulthe, J., Bokemark, L., & Wikstrand, J. (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.01036.x · Cited by 49
Bohlen, H. G. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00818.2003 · Cited by 49
Banerjee, D., Mayoral, A. R., Chitalia, N., & Kaski, J. C. (2011) · Clinical Cardiology · doi:10.1002/clc.20901 · Cited by 47
The association between insulin resistance and endotheliopathy
Tooke, J. E. (1999) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.1999.0010s1017.x · Cited by 47
Effects of insulin resistance on endothelial function: possible mechanisms and clinical implications
Tousoulis, D., Tsarpalis, K., Cokkinos, D. V., & Stefanadis, C. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00818.x · Cited by 45
HORIO, T., Suzuki, M., Takamisawa, I., SUZUKI, K., Hiuge, A., Yoshimasa, Y., & Kawano, Y. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2005.05.035 · Cited by 42
Mikhail, N. E., & Tuck, M. L. (2000) · Current Hypertension Reports · doi:10.1007/s11906-000-0074-3 · Cited by 42
Insulin Resistance and Insulin Sensitizers
Stümvoll, M., & Häring, H. U. (2001) · Hormone Research in Paediatrics · doi:10.1159/000063466 · Cited by 42
The vascular endothelium in diabetes—a therapeutic target?
Mather, K. J. (2013) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-013-9237-9 · Cited by 41
Protein Metabolism in Human Obesity: A Shift in Focus From Whole‐Body to Skeletal Muscle
Katsanos, C. S., & Mandarino, L. J. (2010) · Obesity · doi:10.1038/oby.2010.290 · Cited by 42
Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia
ter Avest, E., Abbink, E. J., Graaf, J. D., Tack, C. J., & Stalenhoef, A. F. H. (2005) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2005.01549.x · Cited by 38
Self-citationRennings, A. J. M., Smits, P., Stewart, M. W., & Tack, C. J. (2006) · Diabetes Care · doi:10.2337/diacare.29.03.06.dc05-01467 · Cited by 37
Self-citationObesity lowers hyperglycemic threshold for impaired in vivo endothelial nitric oxide function
Bohlen, H. G., & Nase, G. P. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00019.2002 · Cited by 37
Mulder, A. H., van Dijk, A. P. J., Smits, P., & Tack, C. J. (2008) · Microcirculation · doi:10.1080/10739680701610681 · Cited by 35
Self-citationEffect of salvianolic acid A on vascular reactivity of streptozotocin-induced diabetic rats
Wang, S., Yang, X., Tian, S., Yang, H., & Du, G. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.07.018 · Cited by 33
Gatenby, V. K., & Kearney, M. T. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.528930 · Cited by 32
Patik, J. C., Christmas, K. M., Hurr, C., & Brothers, R. M. (2015) · Microvascular Research · doi:10.1016/j.mvr.2015.11.007 · Cited by 29
New insights into mechanisms of endothelial insulin resistance in type 2 diabetes
Padilla, J., Manrique‐Acevedo, C., & Martinez‐Lemus, L. A. (2022) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00537.2022 · Cited by 29
Metadata
- Authors
- Tack, C. J. J., Ong, M. K. E., Lutterman, J. A., & Smits, P.
- Affiliations
- Radboud University Nijmegen (NL)
- ORCID
- Tack, C. J. J.
- Venue
- Diabetologia
- Published
- 1998-04-21
- Volume
- 41
- Issue
- 5
- Pages
- 569-576
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2040855107
- Semantic Scholar
- 9797f8f079c36c2855b3d263a5af040730aefdb6
- Cited by
- 177
- References
- 37
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 3 · 2022: 2 · 2021: 1 · 2020: 2 · 2019: 1 · 2017: 1 · 2015: 4 · 2014: 5 · 2013: 10 · 2012: 2
- FWCI
- 6.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Keywords
- insulin resistance, obesity, troglitazone, endothelial function, nitric oxide, forearm blood flow, acetylcholine, sodium nitroprusside, L-NMMA, glucose uptake, blood pressure, neurohumoral response, hyperinsulinemia
- MeSH terms
- Troglitazone, Acetylcholine, Adult, Analysis of Variance, Blood Glucose, Cardiovascular System, Chromans, Dose-Response Relationship, Drug, Double-Blind Method, Endothelium, Vascular, Enzyme Inhibitors, Fasting, Female, Forearm, Hemodynamics, Humans, Hyperinsulinism, Hypoglycemic Agents, Insulin, Insulin Resistance, Lipids, Male, Middle Aged, Nitroprusside, Obesity, Reference Values, Regional Blood Flow, Thiazoles, Vasodilation, Vasodilator Agents, Glucose Clamp Technique, Biomarkers, Case-Control Studies, Cross-Over Studies, omega-N-Methylarginine, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
